Cargando…

Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study

PURPOSE: As protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro Ben David, Shirley, Mizrahi, Barak, Rahamim-Cohen, Daniella, Supino-Rosin, Lia, Shahar, Arnon, Hermoni-Alon, Sharon, Fremder Sacerdote, Ariela, Irony, Angela, Lazar, Rachel, Kalkstein, Nir, Lustig, Yaniv, Indenbaum, Victoria, Landsberger, Daniel, Mizrahi-Reuveni, Miri, Shapira, Shirley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148186/ https://www.ncbi.nlm.nih.gov/pubmed/35641358 http://dx.doi.org/10.1016/j.vaccine.2022.05.051

Ejemplares similares

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel
por: Kertes, Jennifer, et al.
Publicado: (2022)

Smoking cessation – better together: A retrospective cohort study
por: Adler, Limor, et al.
Publicado: (2023)

Post-acute sequelae of COVID-19 infection
por: Jennifer, Kertes, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study
por: Mizrahi Reuveni, Miri, et al.
Publicado: (2023)

Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey
por: Shapiro Ben David, Shirley, et al.
Publicado: (2021)

Smoking quit rates among patients receiving pharmacotherapy who received general practitioner counselling versus intensive counselling: a retrospective cohort study
por: Yehoshua, Ilan, et al.
Publicado: (2022)

Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study
por: Adler, Limor, et al.
Publicado: (2023)

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
por: Patalon, Tal, et al.
Publicado: (2022)

Data-Driven Assessment of Adolescents’ Mental Health During the COVID-19 Pandemic
por: Bilu, Yonatan, et al.
Publicado: (2023)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Dry needling for the treatment of acute myofascial pain syndrome in general practitioners’ clinics: a cohort study
por: Yehoshua, Ilan, et al.
Publicado: (2022)

Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19
por: Mizrahi, Barak, et al.
Publicado: (2021)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Impact on Patient Management of a Novel Host Response Test for Distinguishing Bacterial and Viral Infections: Real World Evidence from the Urgent Care Setting
por: Kalmovich, Boaz, et al.
Publicado: (2023)

876. Real-world impact of a novel host response test for distinguishing between bacterial and viral infections in pediatric patients at ten Urgent Care Centers
por: David, Shirley Shapiro Ben, et al.
Publicado: (2023)

PB1941: MIND-BODY INTERVENTION PROLONGS LYMPHOCYTE DOUBLING TIME AND TREATMENT-FREE SURVIVAL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Shapira, Shirley, et al.
Publicado: (2023)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

98. A nationwide intervention to improve pneumococcal vaccination rate among immunocompromised individuals
por: David, Shirley Shapiro Ben, et al.
Publicado: (2022)

A Nationwide Digital Multidisciplinary Intervention Aimed at Promoting Pneumococcal Vaccination in Immunocompromised Patients
por: Shapiro Ben David, Shirley, et al.
Publicado: (2023)

Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting
por: Ben-Tov, Amir, et al.
Publicado: (2022)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study
por: Mizrahi, Barak, et al.
Publicado: (2023)

Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study
por: Adler, Limor, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Highly Sensitive and Specific SARS-CoV-2 Serological Assay Using a Magnetic Modulation Biosensing System
por: Avivi-Mintz, Shira, et al.
Publicado: (2021)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

What Factors Increase the Risk of Complications in SARS-CoV-2–Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization
por: Yanover, Chen, et al.
Publicado: (2020)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021
por: Bassal, Ravit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orvcb41ttn0muvqtmd4q1bura2